The MAPK and AMPK Signalings: Interplay and Implication in Targeted Cancer Therapy

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2020 Aug 19

PMID 32807225

Citations 201

Authors

Jimin Yuan

Xiaoduo Dong

Jiajun Yap

Jiancheng Hu

Affiliations

Soon will be listed here.

Abstract

Cancer is characterized as a complex disease caused by coordinated alterations of multiple signaling pathways. The Ras/RAF/MEK/ERK (MAPK) signaling is one of the best-defined pathways in cancer biology, and its hyperactivation is responsible for over 40% human cancer cases. To drive carcinogenesis, this signaling promotes cellular overgrowth by turning on proliferative genes, and simultaneously enables cells to overcome metabolic stress by inhibiting AMPK signaling, a key singular node of cellular metabolism. Recent studies have shown that AMPK signaling can also reversibly regulate hyperactive MAPK signaling in cancer cells by phosphorylating its key components, RAF/KSR family kinases, which affects not only carcinogenesis but also the outcomes of targeted cancer therapies against the MAPK signaling. In this review, we will summarize the current proceedings of how MAPK-AMPK signalings interplay with each other in cancer biology, as well as its implications in clinic cancer treatment with MAPK inhibition and AMPK modulators, and discuss the exploitation of combinatory therapies targeting both MAPK and AMPK as a novel therapeutic intervention.

Citing Articles

High-temperature requirement serine protease A2 inhibitor UCF-101 ameliorates damaged neurons in traumatic brain-injured rats by the AMPK/NF-κB pathway.

Qiu T, Jin Z, Fu Z, Yan X, Zhan C, Zheng H Open Life Sci. 2025; 20(1):20220971.

PMID: 40059880 PMC: 11889502. DOI: 10.1515/biol-2022-0971.

Novel 5,6-dichlorobenzimidazole derivatives as dual BRAF and BRAF inhibitors: design, synthesis, anti-cancer activity and molecular dynamics simulations.

Temirak A, El Kerdawy A, Nageeb A, Abdel-Mohsen H BMC Chem. 2025; 19(1):45.

PMID: 39985108 PMC: 11844072. DOI: 10.1186/s13065-025-01402-8.

A supramolecular FRET signal amplification nanoprobe for high contrast and synchronous imaging of cell surface receptor homodimers/heterodimers.

Wang Y, Yao F, Song L, Zhang M, Gong Z, Zhao Y Chem Sci. 2025; 16(11):4732-4740.

PMID: 39968283 PMC: 11831222. DOI: 10.1039/d4sc08004a.

Implication of protein post translational modifications in gastric cancer.

Song H, Zhang M, Guo C, Guo X, Ma Y, Ma Y Front Cell Dev Biol. 2025; 13:1523958.

PMID: 39968176 PMC: 11833226. DOI: 10.3389/fcell.2025.1523958.

Molecular principles underlying aggressive cancers.

Nussinov R, Yavuz B, Jang H Signal Transduct Target Ther. 2025; 10(1):42.

PMID: 39956859 PMC: 11830828. DOI: 10.1038/s41392-025-02129-7.

References

Strohecker A, Guo J, Karsli-Uzunbas G, Price S, Chen G, Mathew R . Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors. Cancer Discov. 2013; 3(11):1272-85. PMC: 3823822. DOI: 10.1158/2159-8290.CD-13-0397. View

Jansen H, Ruckert B, Lurz R, Bister K . Two unrelated cell-derived sequences in the genome of avian leukemia and carcinoma inducing retrovirus MH2. EMBO J. 1983; 2(11):1969-75. PMC: 555395. DOI: 10.1002/j.1460-2075.1983.tb01686.x. View

Sprenkle A, DAVIES S, Carling D, Hardie D, Sturgill T . Identification of Raf-1 Ser621 kinase activity from NIH 3T3 cells as AMP-activated protein kinase. FEBS Lett. 1997; 403(3):254-8. DOI: 10.1016/s0014-5793(97)00062-8. View

Long G, Weber J, Infante J, Kim K, Daud A, Gonzalez R . Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. J Clin Oncol. 2016; 34(8):871-8. DOI: 10.1200/JCO.2015.62.9345. View

Bryant K, Stalnecker C, Zeitouni D, Klomp J, Peng S, Tikunov A . Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nat Med. 2019; 25(4):628-640. PMC: 6484853. DOI: 10.1038/s41591-019-0368-8. View

Andersson U, Filipsson K, Abbott C, Woods A, Smith K, Bloom S . AMP-activated protein kinase plays a role in the control of food intake. J Biol Chem. 2004; 279(13):12005-8. DOI: 10.1074/jbc.C300557200. View

Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z . AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab. 2013; 17(1):113-24. PMC: 3545102. DOI: 10.1016/j.cmet.2012.12.001. View

Hu C, Wu Z, Wang J . Amino acids and autophagy: their crosstalk, interplay and interlock. Amino Acids. 2015; 47(10):2035-6. DOI: 10.1007/s00726-015-2098-7. View

Dhillon A, Yip Y, Grindlay G, Pakay J, Dangers M, Hillmann M . The C-terminus of Raf-1 acts as a 14-3-3-dependent activation switch. Cell Signal. 2009; 21(11):1645-51. DOI: 10.1016/j.cellsig.2009.07.001. View

10.

Ekerot M, Stavridis M, Delavaine L, Mitchell M, Staples C, Owens D . Negative-feedback regulation of FGF signalling by DUSP6/MKP-3 is driven by ERK1/2 and mediated by Ets factor binding to a conserved site within the DUSP6/MKP-3 gene promoter. Biochem J. 2008; 412(2):287-98. PMC: 2474557. DOI: 10.1042/BJ20071512. View

11.

Shen C, Yuan P, Perez-Lorenzo R, Zhang Y, Lee S, Ou Y . Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation. Mol Cell. 2013; 52(2):161-72. PMC: 3892895. DOI: 10.1016/j.molcel.2013.08.044. View

12.

Downward J . Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003; 3(1):11-22. DOI: 10.1038/nrc969. View

13.

Goetz E, Ghandi M, Treacy D, Wagle N, Garraway L . ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors. Cancer Res. 2014; 74(23):7079-89. PMC: 4300142. DOI: 10.1158/0008-5472.CAN-14-2073. View

14.

Therrien M, Chang H, Solomon N, Karim F, Wassarman D, Rubin G . KSR, a novel protein kinase required for RAS signal transduction. Cell. 1995; 83(6):879-88. DOI: 10.1016/0092-8674(95)90204-x. View

15.

Sosman J, Kim K, Schuchter L, Gonzalez R, Pavlick A, Weber J . Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012; 366(8):707-14. PMC: 3724515. DOI: 10.1056/NEJMoa1112302. View

16.

Gleason C, Lu D, Witters L, Newgard C, Birnbaum M . The role of AMPK and mTOR in nutrient sensing in pancreatic beta-cells. J Biol Chem. 2007; 282(14):10341-51. DOI: 10.1074/jbc.M610631200. View

17.

Taylor S, Shaw A, Hu J, Meharena H, Kornev A . Pseudokinases from a structural perspective. Biochem Soc Trans. 2013; 41(4):981-6. PMC: 4399968. DOI: 10.1042/BST20130120. View

18.

Choo A, Kim S, Vander Heiden M, Mahoney S, Vu H, Yoon S . Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Mol Cell. 2010; 38(4):487-99. PMC: 2896794. DOI: 10.1016/j.molcel.2010.05.007. View

19.

Petti C, Vegetti C, Molla A, Bersani I, Cleris L, Mustard K . AMPK activators inhibit the proliferation of human melanomas bearing the activated MAPK pathway. Melanoma Res. 2012; 22(5):341-50. DOI: 10.1097/CMR.0b013e3283544929. View

20.

Kolch W, Heidecker G, Lloyd P, Rapp U . Raf-1 protein kinase is required for growth of induced NIH/3T3 cells. Nature. 1991; 349(6308):426-8. DOI: 10.1038/349426a0. View